Idemitsu Kosan Company, Limited

Chiba University

Other

University of California

Otsuka Pharmaceutical Company, Limited

Meiji Seika Kaisha, Ltd.

Daihatsu Motor Company, Ltd.

Daiichi Pure Chemicals Co., Ltd.

Tatematsu Mold Works Co., Ltd.

Idemetsu Kosan Co., Ltd.

Idenitsu Kosan Co., Ltd.

Iyo, Masaomi

Hashimoto, Kenji

Kenji Hashimoto

Kimihiro Yuasa

Shunji Uchida

Kazuharu Morita

Satoshi Hachiya

Masaomi Iyo

Bruce D Hammock

Tetsuo Fujimoto

Sung Hee Hwang

Jun Yang

Kaori Koike

Christophe H Morisseau

Kazuhito Ishida

Takeo Yoshikawa

Haruya Hashimoto

Mikael Landen

Shinya Takemura

Yuji Saito

Ayumu Imaoka

Takashi Futamura

Tsuyoshi Goromaru

Michiko Nakazato

Yohko Maeda

Yoshie Kitao

Noriko Yoshimi

Hajime Sasaki

Eiji Shimizu

Toshiya Inada

Qian Ren

Yoshimi Iwayama

Hiroki Koizumi

Provided herein are methods of preventing, reducing, ameliorating, mitigating, inhibiting, treating and/or reversing a neurodevelopmental disorder related to prenatal maternal immune activation in an individual in need thereof comprising administering to said individual an agent that increases the level of epoxy-fatty acids wherein said individual experienced maternal immune activation one or more times during gestation. Also provided herein are methods of preventing, reducing, ameliorating, mitigating, inhibiting treating and/or reversing schizophrenia or autism spectrum disorder an individual comprising administering to said individual an agent that increases the level of epoxy-fatty acids.

Treatment of neurodevelopmental disorders

Provided are methods of preventing, delaying, mitigating, reducing and/or inhibiting alpha-synuclein aggregates in the brains of a subject at risk of developing or suffering a cognitive disease associated with, caused and/or mediated at least in part by alpha-synuclein aggregates, for example, Parkinson's Disease or Dementia with Lewy Bodies (DLB).

Methods of inhibiting formation of alpha synuclein aggregates

This preventive or therapeutic agent for inflammatory diseases or bone diseases, and this pharmaceutical composition for preventing or treating inflammatory diseases or bone diseases include, as effective components, a compound represented by formula (1) or a pharmaceutically acceptable salt thereof. [In formula (1), X is a hydrogen atom, a halogen atom, or a C-Calkyl group that may be substituted; Ris a C-Calkyl group that may be substituted, a C-Calkenyl group that may be substituted, or a C-Caryl group that may be substituted; and one or more hydrogen atoms may be substituted with deuterium atoms.]

Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases

Provided is a novel compound having rapid and long-lasting therapeutic effects on diseases exhibiting depressive symptoms. Specifically, provided are an agent for prevention and/or treatment of a depressive symptom, consisting of R(&#x2212;)-ketamine or a pharmacologically acceptable salt thereof, and a pharmaceutical composition for prevention and/or treatment of a depressive symptom, comprising R(&#x2212;)-ketamine or a pharmacologically acceptable salt thereof in an effective amount for reducing a depressive symptom, and being substantially free of S(+)-ketamine, and a pharmacologically acceptable salt thereof.

Application of R-ketamine and salt thereof as pharmaceuticals

This invention provides methods for preventing, mitigating, ameliorating and/or controlling psychiatric disorders, including depression, major depression, bipolar disorder, schizophrenia and substance abuse (including addiction and dependence) by administration of an agent that increases epoxy-fatty acids (e.g., an inhibitor of soluble epoxide hydrolase), as sole active agent or in combination with another agent (e.g., an antidepressant, an antipsychotic, an anxiolytic). When co-administered in combination with another agent, one or both agent may be administered at a subtherapeutic dose.

Methods of treating mental disorders

Methods of diagnosing, confirming a diagnosis of, and determining a predisposition for a bipolar disorder in a subject are provided. An amount of at least one of biomarker from the cerebrospinal fluid and/or serum of a subject is measured, for example, isocitric acid. The amount of the at least one biomarker can be compared with a control amount of the at least one biomarker in a corresponding sample collected from a subject without the bipolar disorder. An increase or decrease in the amount of the particular biomarker or biomarkers measured can be indicative that the subject has the bipolar disorder or a predisposition for the bipolar disorder. Methods of identifying a compound for preventing and/or treating a bipolar disorder are also provided based on the expression level of an isocitric acid dehydrogenase 3 alpha and/or beta-subunit gene, and/or based on one or more metabolite biomarker.

Methods of diagnosing bipolar disorders and screening for therapeutic compounds

A medicinal preparation for preventing and/or treating psychoneurotic diseases such as integration dysfunction and Alzheimer's disease which contains tropisetron or its pharmaceutically acceptable salt as the active ingredient.

Remedy for psychoneurotic diseases

The invention relates to a medicament for preventing and/or treating schizophrenia which comprises as an active ingredient cilostazol or a pharmaceutically acceptable salt thereof.

Medicament for treating schizophrenia comprising cilostazol

The present invention provides a diagnostic agent for eating disorders comprising as an active ingredient an antibody against brain-derived neurotrophic factor, and a method for detecting eating disorders comprising measuring of the concentration of a brain-derived neurotrophic factor in blood. Particularly, the eating disorders can easily be diagnosed by measuring the concentration of a brain-derived neurotrophic factor in blood of the patients with an antibody against brain-derived neurotrophic factor and a labeled antibody against brain-derived neurotrophic factor.

Diagnostic and examination method for eating disorder

An air bag cover body forming apparatus, comprising forming molds (A,B), groove-forming blades (), and support rods (), wherein the forming molds form a cavity () for forming a resin air bag cover body () having air bag door parts, the groove-forming blades form rupture grooves () determining the air bag door parts in the air bag cover body, and the support rods support the air bag door parts of the air bag cover body formed in the cavity. The forming molds comprising movable cores () reciprocatingly movable between a position where the molds are allowed to abut on the air bag cover body and a position where the molds are separated from the air bag cover body, wherein when the cores are separated from the air bag door parts, the support rods are allowed to abut on the air bag door parts to prevent an excessive stress concentration from occurring in the rupture grooves.

Air bag cover body forming apparatus

Method for therapeutically treating tardive dyskinesia and uses thereof

A ferroelectric liquid crystal composition comprising (A) a ferroelectric liquid crystal material and (B) a non-liquid-crystalline polymeric material;

Ferroelectric liquid crystal composition, liquid crystal optical device

Growing community of inventors

Chiba, Japan

Kenji Hashimoto